Richard Bernstein Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Richard Bernstein Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,199	Closed	-$1.43M	–	227
2019 Q4	$1.43M	Hold	13,199	–	–	0.05%	189
2019 Q3	$1.29M	Hold	13,199	–	–	0.04%	200
2019 Q2	$1.73M	Hold	13,199	–	–	0.06%	186
2019 Q1	$1.78M	Buy	+13,199	New	+$1.64M	0.06%	211
2016 Q1	–	Sell	-19,821	Closed	-$3.78M	–	278
2015 Q4	$3.78M	Hold	19,821	–	–	0.48%	81
2015 Q3	$3.1M	Hold	19,821	–	–	0.42%	87
2015 Q2	$3.58M	Buy	19,821 +3,511	+22%	+$606K	0.43%	96
2015 Q1	$2.83M	Hold	16,310	–	–	0.37%	92
2014 Q4	$3.02M	Hold	16,310	–	–	0.31%	125
2014 Q3	$2.71M	Hold	16,310	–	–	0.29%	124
2014 Q2	$2.55M	Hold	16,310	–	–	0.3%	125
2014 Q1	$2.48M	Buy	16,310 +9,104	+126%	+$1.45M	0.35%	96
2013 Q4	$959K	Hold	7,206	–	–	0.19%	180
2013 Q3	$837K	Hold	7,206	–	–	0.25%	144
2013 Q2	$665K	Buy	+7,206	New	+$694K	0.22%	167

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Richard Bernstein Advisors's ALXN Position: Q1 2020 in Review

Richard Bernstein Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 13,199 shares — an estimated $1.43M sold.

Richard Bernstein Advisors first reported a position in ALXN in Q2 2013 and held it in 15 quarters. The position peaked at $3.78M in Q4 2015. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Richard Bernstein Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Richard Bernstein Advisors sold 13,199 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.43M.
Richard Bernstein Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Richard Bernstein Advisors's Alexion Pharmaceuticals position peaked at $3.78M in Q4 2015.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Richard Bernstein Advisors's 13F filing for Q1 2020, filed 13 May 2020.